Lesson 8 - Medication Titration
1. Introduction
Medication titration is one of the most important practical skills in ADHD prescribing. Choosing an appropriate medication is only the beginning of treatment. The prescriber must then establish the dose that provides meaningful improvement in ADHD symptoms and day-to-day functioning while keeping adverse effects acceptable and maintaining appropriate physical and mental health monitoring.
Titration should therefore be understood as a structured clinical process rather than simply a sequence of dose increases. The aim is not to reach the highest licensed dose, nor to increase medication until all ADHD symptoms disappear. Instead, treatment is adjusted according to the individual patient's response, balancing symptom improvement, functional benefit, duration of effect, tolerability, patient preference and safety.
This process can be particularly nuanced because response to ADHD medication varies considerably between individuals. A relatively low dose may provide excellent symptom control for one patient, while another may require careful escalation through several doses before obtaining worthwhile benefit. Some patients experience a clear improvement but troublesome adverse effects; others have partial benefit, inadequate duration of action, or little meaningful response despite apparently adequate treatment.
Good titration therefore requires the prescriber to repeatedly answer several clinical questions: Is the medication working? Is the improvement clinically meaningful? Is it lasting for the parts of the day when it is needed? Is the medication well tolerated? Is it safe to continue? And should the dose be increased, maintained, reduced, or the treatment strategy reconsidered?
This lesson builds on the earlier teaching about selecting and starting ADHD medication. It focuses on what happens after the first prescription: reviewing response systematically, adjusting treatment safely, recognising when further dose escalation is unlikely to be helpful, and determining when a patient has reached an optimised treatment regimen.
By developing a structured approach to titration, prescribers can move beyond simply asking whether a medication is "helping" and instead make thoughtful, evidence-informed decisions about effectiveness, functioning, tolerability, duration and safety. These skills form the bridge between starting ADHD medication and the longer-term monitoring and maintenance of successful treatment.
2. Learning Outcomes
By the end of this lesson, learners should be able to:
Explain the aims and principles of ADHD medication titration, including the balance between symptom improvement, functional benefit, tolerability and safety.
Conduct a structured titration review, assessing ADHD symptoms, functioning, duration of medication effect, adverse effects and relevant physical and mental health parameters.
Make appropriate dose-adjustment decisions, including when to increase, maintain or reduce a dose and when further titration may not be appropriate.
Recognise and manage common problems encountered during titration, including partial response, inadequate duration of effect, rebound symptoms and dose-related adverse effects.
Identify when a medication trial has been adequate but unsuccessful and when an alternative preparation or medication should be considered.
Determine when treatment has been optimised and titration can end, allowing transition to longer-term medication monitoring and maintenance.
3. The Lecture
What Do We Mean by Titration?
When we prescribe ADHD medication for the first time, we have not yet established the right dose for that individual. We may know the recommended starting dose, the usual dose range and the maximum licensed dose, but none of these tells us what the patient's optimal dose will be.
Titration is the process of systematically adjusting medication while observing what happens to ADHD symptoms, functional impairment and adverse effects. NICE recommends recording symptoms, impairment and adverse effects at baseline and at each dose change, with regular specialist review during titration. The dose is adjusted until optimisation is achieved: meaningful improvement in symptoms and functioning with adverse effects that remain tolerable.
That definition is important because titration is sometimes mistakenly understood as:
Start low → increase regularly → reach the maximum dose.
That is not the objective. A better way of thinking about it is:
Start appropriately → assess response → adjust → reassess → stop when optimised.
The final dose may therefore be relatively low, somewhere in the middle of the licensed range, or towards the upper end. The dose is determined by the patient's clinical response rather than by an expectation that everyone should progress through the same sequence.
The Four Questions at Every Titration Review
A useful approach in clinical practice is to organise every titration review around four questions:
1. Is it working?
Has there been improvement in the ADHD symptoms that were causing difficulty before treatment?
2. Is that improvement translating into better functioning?
Are concentration, organisation, emotional regulation, school or occupational functioning, relationships, or everyday activities actually improving?
3. How long is the benefit lasting?
When does the medication begin to work? When does the benefit appear to wear off? Does its duration match the patient's needs?
4. Is it well tolerated and safe?
Are there adverse effects? Have appetite, sleep, mood or physical observations changed? Is there anything that makes further dose escalation inappropriate?
These four questions provide considerably more useful information than simply asking:
"How are you getting on with the medication?"
Patients will sometimes answer that question with "fine", even when careful questioning reveals that the medication lasts only four hours, appetite has substantially reduced, or there has been very little improvement in ADHD symptoms.
Assessing Effectiveness
Look Beyond "Better" or "Worse"
Medication response should be assessed against the difficulties identified before treatment.
Suppose an adolescent had significant difficulty completing lessons, frequently left their seat, required repeated prompting at home and took several hours to complete homework. At review, asking whether their ADHD is "better" provides relatively little information.
Instead, explore what has actually changed.
Can they remain engaged for longer in lessons?
Are fewer prompts required?
Are they completing more work?
Are impulsive interruptions less frequent?
Is homework more manageable?
Are family interactions improving?
NICE explicitly includes improvement in education, employment and relationships within its concept of dose optimisation.
This is why functional change matters just as much as symptom change.
A patient might report that concentration feels somewhat better, but if there has been no discernible improvement in the activities that treatment was intended to help, we should be cautious about assuming that the medication has been adequately optimised.
Establish Treatment Targets Before You Lose Them
One practical problem during titration is that the original treatment targets can gradually disappear from view.
Before starting medication, it is therefore useful to identify several concrete difficulties that can subsequently be revisited.
For a child, these might include completing classroom work, remaining seated during lessons, managing homework and reducing impulsive conflict with siblings.
For an adult, they might include completing administrative tasks, sustaining attention during meetings, arriving at appointments on time or completing household tasks without repeatedly moving between activities.
At subsequent reviews, return to these examples.
This makes the assessment much more clinically meaningful than repeatedly asking for a global impression of whether medication is helping.
Assessing Response Across Settings
ADHD exists across everyday environments, and medication response should therefore not be assessed solely from what happens during a clinic appointment.
For children and young people, information from parents and school can be particularly valuable. NICE recommends using standard scales to record symptoms and adverse effects during titration, including observer ratings from parents and teachers.
Sometimes different observers will report apparently contradictory experiences.
A parent might say:
"I don't think it is doing very much."
The school may report:
"Concentration is dramatically better."
That does not necessarily mean somebody is wrong.
The medication may be working very well during school hours but wearing off before the child returns home.
Alternatively, the demands of the two environments may be different. A highly structured classroom and a less structured evening at home can expose different difficulties.
When reports conflict, the prescriber's task is therefore not simply to decide which observer is correct. The more useful question is:
What might explain the difference?
Dose–Response Is Individual
One of the most important principles for new ADHD prescribers is that there is no reliable way of predicting an individual's optimal stimulant dose from the apparent severity of their ADHD.
More severe ADHD does not automatically mean that somebody will require a higher dose.
Similarly, body size alone does not determine the optimal stimulant dose.
Two patients with apparently similar ADHD presentations may respond very differently to the same preparation. One may obtain excellent benefit at a relatively low dose. Another may experience little benefit until the medication has been cautiously increased.
This is precisely why titration is necessary.
We are conducting a structured therapeutic trial in an individual patient.
Deciding Whether to Increase the Dose
At each review, there are several possible decisions. Increasing the dose is only one of them.
Partial Benefit With Good Tolerability
This is perhaps the most straightforward situation.
Imagine an adult taking a modified-release stimulant who reports:
"I'm definitely more focused. I'm getting through much more work, but I still get distracted quite easily and I think there is room for improvement."
Their sleep and appetite are unchanged, they report no significant adverse effects, and physical monitoring is satisfactory.
This is a situation in which further titration may reasonably be considered, provided the proposed dose remains appropriate for that medication.
The important point is that there is already evidence of response, but treatment has not yet been optimised.
Good Benefit With Minimal Residual Symptoms
Now consider another patient who reports markedly improved concentration, organisation and task completion. Their family has noticed substantial improvement, occupational functioning is better and adverse effects are minimal.
There may still be occasional distractibility.
Should the dose automatically be increased?
Not necessarily.
The goal of medication is not to eliminate every characteristic associated with ADHD. Increasing an already effective dose in pursuit of complete symptom suppression may simply expose the patient to additional adverse effects without producing meaningful functional benefit.
Sometimes the correct titration decision is:
Keep the dose unchanged.
No Benefit and No Adverse Effects
This requires more thought.
Before concluding that the medication is ineffective, ask:
Has an adequate dose actually been reached?
Has it been taken consistently?
Is it being taken correctly?
Has the trial been sufficiently long for the medication being used?
Is the formulation behaving as expected?
Are we measuring the right outcomes?
If the patient remains at an early titration dose, lack of benefit may simply indicate that further cautious escalation is required.
However, repeatedly increasing a medication indefinitely despite no meaningful response is not good titration. At some point, the prescriber must decide whether an adequate therapeutic trial has occurred and whether an alternative treatment strategy is appropriate.
Adverse Effects During Titration
Adverse effects should be actively sought rather than waiting for patients to volunteer them.
Common areas to explore include appetite, weight, gastrointestinal symptoms, headache, sleep, cardiovascular symptoms, mood and behavioural changes.
The important clinical question is not simply:
"Is there a side effect?"
It is:
"How significant is it, and what should we do about it?"
Some adverse effects are mild and transient. Others may become increasingly problematic as the dose increases. Some require modification of treatment, while particular symptoms or physical findings may require more urgent assessment.
The prescriber therefore needs to consider the trajectory of adverse effects alongside the trajectory of benefit.
Benefit and Adverse Effects Must Be Considered Together
Consider a young person whose concentration improves considerably as methylphenidate is increased.
At the first dose, benefit is modest and there are no adverse effects.
At the next dose, benefit is clearly better and appetite is mildly reduced.
Following another increase, concentration improves slightly further, but appetite becomes substantially suppressed and sleep deteriorates.
It would be misleading to describe the highest dose simply as "the most effective".
The additional benefit may be relatively small while the burden of adverse effects has increased considerably.
The previous dose may therefore represent the better balance.
This illustrates a fundamental principle:
The optimal dose is not necessarily the dose producing the greatest symptom reduction. It is the dose producing the best overall balance between clinically meaningful benefit and tolerability.
Duration of Effect
Dose and Duration Are Not the Same Question
One of the most common errors during titration is interpreting inadequate duration as inadequate strength.
Suppose a patient says:
"The medication works really well until about 3 pm, and then everything falls apart."
The immediate temptation may be to increase the morning dose.
But first ask what happens while the medication is working.
If concentration and impulse control are excellent from the morning until mid-afternoon, the problem may not be insufficient therapeutic effect. The problem may be duration of coverage.
Depending on the medication, formulation, individual circumstances and prescribing guidance, the clinical solution may involve reconsidering formulation, timing or the overall dosing strategy rather than simply escalating the morning dose.
This distinction becomes particularly important with stimulant medication.
Always separate:
How well does it work?
from:
How long does it work?
Wearing Off and Rebound
Patients sometimes describe deterioration as stimulant medication wears off.
This may simply represent the return of underlying ADHD symptoms. In other cases, there may be a more pronounced period of irritability, restlessness or emotional dysregulation around the end of the medication's effect.
Careful history-taking helps distinguish these possibilities.
Ask:
When does it happen?
How long does it last?
Is the behaviour simply returning to the pre-medication baseline, or is it temporarily worse?
Does it correspond consistently with the expected end of medication action?
Do food, fatigue, school demands or other environmental factors contribute?
Do not automatically interpret every difficult evening as evidence that the medication dose is inadequate.
Stimulants and Non-Stimulants Require Different Expectations
Another important part of titration is understanding the pharmacological characteristics of the medication being prescribed.
With stimulant medication, therapeutic effects can often be observed relatively quickly. This allows the clinician to assess the effects associated with individual doses comparatively rapidly.
Non-stimulant medication requires a different mindset. Clinical benefit may emerge more gradually, meaning that repeatedly changing the dose before there has been sufficient opportunity to assess response can make the trial difficult to interpret.
Prescribers should therefore titrate according to the relevant prescribing information and current BNF/BNFC guidance rather than applying one universal titration schedule to every ADHD medication. NICE similarly recommends titrating against symptoms and adverse effects in accordance with the BNF or BNFC.
Physical Monitoring During Titration
Medication titration is not solely an assessment of ADHD symptoms.
Physical health monitoring remains an integral part of safe prescribing.
Depending on the medication and patient's circumstances, this includes appropriate monitoring of cardiovascular parameters, weight and growth, alongside enquiry about clinically relevant physical symptoms.
The key principle is that physical observations should inform prescribing decisions, rather than becoming a box-ticking exercise.
If a measurement changes significantly, consider:
Is the change clinically meaningful?
Could medication be contributing?
Should the measurement be repeated?
Does treatment need modifying?
Is further medical assessment required?
The aim is not merely to collect observations. It is to interpret them.
Mental State During Titration
Changes in mental state also need to be considered.
Ask about mood, anxiety, irritability, emotional regulation and sleep, particularly when there has been a temporal relationship with starting medication or changing the dose.
A common mistake is to assume that every new symptom occurring during titration must be a medication adverse effect.
Equally, it is unsafe to assume that every change is unrelated to medication.
Think temporally.
Did the difficulty exist before treatment?
Did it begin after medication was introduced?
Did it change after a dose increase?
Does it appear during the medication's active period or when it is wearing off?
Does it occur on days when medication is not taken?
This type of questioning often provides considerably more information than simply recording "irritability – yes".
When Titration Needs to Be Slower
Not every patient should progress through titration at the same pace.
NICE advises slower titration and more frequent monitoring when ADHD coexists with certain neurodevelopmental disorders, mental health conditions or physical health conditions. Examples include autism, tic disorders, intellectual disability, anxiety, depression, bipolar disorder, eating disorders, substance misuse, cardiac disease and epilepsy.
The practical message is straightforward:
Greater clinical complexity should generally increase caution rather than accelerate prescribing.
This does not mean that these patients cannot receive effective ADHD medication. It means that changes may need to be made more gradually so that emerging benefits and difficulties can be interpreted safely.
Do Not Change Too Many Variables at Once
This is a simple but important prescribing principle.
If you simultaneously change the medication, dose, formulation and administration time, and the patient subsequently feels much better or much worse, it may be difficult to know why.
Where clinically appropriate, make sufficiently controlled changes that the response remains interpretable.
This is particularly useful when investigating duration problems or adverse effects.
Good titration should generate information.
Every dose change is effectively asking a clinical question:
"Does this adjustment improve the balance of benefit and tolerability?"
If several things change simultaneously, the answer becomes much harder to interpret.
When Should You Stop Increasing?
There are several reasons to stop escalating a dose.
The first is optimisation. The patient has meaningful symptom and functional improvement and treatment is well tolerated. There is no need to increase medication simply because a higher licensed dose exists.
The second is dose-limiting adverse effects. Increasing the medication further is producing more harm than benefit.
The third is lack of meaningful additional benefit. If repeated increases are producing little further improvement, continuing to escalate may not be useful.
The fourth is reaching the appropriate dose limit for that medication or patient.
At this point the clinical question changes from:
"Should I increase it again?"
to:
"Is this medication, formulation and dosing strategy actually the right treatment for this patient?"
Recognising an Unsuccessful Medication Trial
A medication should not be labelled ineffective simply because the starting dose did not work.
Equally, an ineffective medication should not be continued indefinitely because the prescriber is reluctant to change strategy.
Before concluding that a trial has been unsuccessful, establish whether the medication has been taken adequately and whether an appropriate therapeutic trial has occurred.
Then consider the pattern.
Was there no meaningful response despite an adequate trial?
Was there some response but unacceptable adverse effects?
Was there good response but inadequate duration?
Was there good symptom response but little functional improvement?
These are different clinical problems and may lead to different prescribing decisions.
Knowing When Titration Is Complete
Titration ends when treatment has been sufficiently optimised, not when every symptom has disappeared.
NICE describes optimisation in terms of reduced symptoms, positive behavioural change and improvements in important areas of functioning while adverse effects remain tolerable.
In practice, before moving into maintenance treatment, you should be able to describe clearly:
what medication the patient is taking;
what dose and formulation they are taking;
what improvement it produces;
how long the benefit lasts;
whether important residual difficulties remain;
what adverse effects are present;
and whether the treatment remains clinically and physically safe.
If you cannot answer those questions, titration probably has not yet done its job.
A Clinical Example: Following the Whole Titration Journey
Consider a 15-year-old who starts modified-release methylphenidate because ADHD is significantly affecting classroom concentration, task completion, impulsivity and homework.
At the first review, there are no significant adverse effects but little noticeable benefit.
The medication is cautiously increased.
At the next review, teachers describe better concentration during morning lessons and the young person is completing more work. However, difficulties remain significant. Appetite and sleep remain satisfactory.
The dose is increased again.
At the following review, school reports substantial improvement. The young person feels more able to concentrate and less overwhelmed by schoolwork. The family also notices improvement, although homework remains difficult because the medication appears to wear off by late afternoon.
At this stage, simply increasing the dose again without further thought would miss an important distinction.
The medication appears to be effective.
The remaining question concerns duration.
The clinician should therefore explore the timing of benefit carefully and consider whether the formulation or dosing strategy requires adjustment rather than assuming that the patient simply needs "more medication".
Eventually, a regimen is established that provides meaningful coverage across the required period. ADHD symptoms and functioning are substantially improved, physical monitoring is satisfactory, appetite reduction is mild and manageable, and sleep remains good.
There are still occasional difficulties with concentration.
That does not mean titration has failed.
The patient has reached a point at which further dose escalation is unlikely to provide enough additional functional benefit to justify additional exposure or adverse effects.
That is optimisation.
And recognising that point is one of the most important skills in ADHD prescribing.
4. Clinical Perspective
Medication titration is where much of the clinical judgement in ADHD prescribing actually occurs. Starting doses and licensed dose ranges can be looked up. The more difficult skill is deciding what a particular patient's response means and what to do next.
Clinical Pearl: Titrate the Patient, Not the Dose Schedule
A titration schedule provides a framework, but it should never replace clinical judgement. Patients do not need to progress automatically through every available dose.
If a patient has achieved substantial improvement in ADHD symptoms and everyday functioning at a relatively low dose, with good tolerability, there may be no reason to increase further. Conversely, a patient who has obtained only partial benefit may reasonably require further titration if the medication is well tolerated and it remains clinically appropriate to do so.
The question at each review should therefore be:
"What is the clinical reason for changing the dose?"
If you cannot answer that clearly, reconsider whether a change is necessary.
Do Not Chase Complete Symptom Elimination
New prescribers can sometimes become overly focused on eliminating every residual ADHD symptom. This can lead to unnecessary dose escalation.
Medication rarely needs to make somebody completely free of distractibility, impulsivity or restlessness to be successful. The more important question is whether there has been meaningful improvement in the difficulties that were impairing the person's life.
A patient who is functioning well at school or work, managing relationships better and completing important tasks may already have an excellent response despite continuing to experience some ADHD characteristics.
The aim is optimisation, not perfection.
Always Ask What Changed After the Last Dose Increase
One of the most useful questions during titration is:
"What is different on this dose compared with the previous one?"
This encourages comparison rather than simply collecting another snapshot of symptoms.
If increasing from one dose to the next produces substantial additional benefit without meaningful adverse effects, that is useful information.
If the next increase produces almost no additional improvement but causes appetite suppression, insomnia or emotional difficulties, that is equally useful information. The previous dose may have represented the better balance.
Titration should therefore be thought of as finding the point at which additional medication stops producing worthwhile additional benefit.
Separate Effectiveness From Duration
This is one of the most important practical distinctions in stimulant prescribing.
When somebody says that their medication "isn't working", establish exactly what they mean.
They may mean:
"It never really helps."
Or they may mean:
"It works extremely well, but it wears off too early."
Those are very different prescribing problems.
Increasing the dose may sometimes alter duration, but inadequate coverage should not automatically be interpreted as inadequate dose. Explore when benefit begins, when it is strongest and when it disappears.
A simple question is:
"When the medication is working, does it work well enough?"
If the answer is yes, think carefully before assuming that dose escalation is the solution.
Ask About Function, Not Just Symptoms
Patients can find it difficult to quantify changes in concentration. Functional examples are often easier to identify.
Instead of asking only whether concentration has improved, ask what the patient can now do that they struggled to do previously.
For a young person, this might mean completing more work in lessons, requiring fewer prompts, managing homework more independently or getting into fewer impulsive conflicts.
For an adult, it might mean finishing reports, following meetings, responding to emails, managing household tasks or arriving at appointments reliably.
Functional improvement often provides the clearest evidence that treatment is clinically worthwhile.
Clarify Timing Before Attributing Symptoms to Medication
Irritability, anxiety, headaches, tiredness and emotional dysregulation can all arise for many reasons. The fact that something occurs during titration does not necessarily mean that medication caused it.
Establish the timeline.
Was it present before medication?
Did it begin after treatment started?
Did it become worse after a particular dose increase?
Does it occur while the medication is active?
Does it appear specifically when the medication wears off?
Does it occur on days when medication is not taken?
This temporal approach is particularly helpful when distinguishing an adverse effect from rebound, the return of underlying ADHD symptoms, or an unrelated difficulty.
Appetite Requires More Than Asking "Are You Eating?"
Reduced appetite is common with stimulant treatment, but its clinical significance varies considerably.
A patient may report reduced lunchtime appetite while continuing to eat adequately at breakfast and in the evening and maintaining appropriate weight or growth. Another may progressively skip meals and lose clinically significant weight.
Ask about the pattern and consequences of appetite suppression rather than recording appetite as simply "reduced".
In children and young people, growth monitoring is particularly important. NICE provides specific recommendations for monitoring height and weight and strategies to consider when weight loss becomes a clinical concern.
Sleep Problems Need Careful Interpretation
Do not automatically attribute insomnia to stimulant medication.
Ask what sleep was like before treatment. ADHD itself can be associated with difficulties settling to sleep, and behavioural routines, anxiety, screen use and other factors may contribute.
Then establish timing.
When is medication taken?
When does its therapeutic effect appear to finish?
Did the sleep problem emerge after a dose change?
Interestingly, some patients may sleep better when ADHD is effectively treated because evenings become less chaotic and settling becomes easier.
The clinical task is to establish the pattern rather than assume the explanation.
Do Not Ignore Cardiovascular Changes Because the Patient Feels Well
Blood pressure and pulse monitoring are part of medication safety, not optional additions to the symptom review. NICE recommends monitoring heart rate and blood pressure before and after each dose change and every 6 months thereafter.
A patient may report excellent benefit and no subjective adverse effects while physical observations indicate that treatment requires reconsideration.
Equally, an isolated unexpected reading should be interpreted appropriately rather than automatically resulting in a major treatment decision. Consider technique, repeat measurements when appropriate, review previous readings and act according to the clinical circumstances and relevant guidance.
More Medication Is Not Always the Answer to Residual Difficulties
When ADHD symptoms remain problematic, it is tempting to assume that the dose is inadequate.
Consider the wider picture.
A young person may still struggle with homework because medication has worn off, but they may also be exhausted after school, anxious about academic performance or have specific learning difficulties.
An adult may remain disorganised despite substantially improved attention because years of ADHD-related difficulty have left them without effective organisational systems.
Medication can improve the neurocognitive conditions required for functioning. It does not automatically teach study skills, establish routines, repair relationships or remove environmental stressors.
Residual impairment therefore deserves formulation rather than automatic dose escalation.
Be Particularly Careful When Several Things Change Together
Try, where clinically appropriate, to change one meaningful variable at a time.
If the dose, formulation, timing and another medication are all changed simultaneously, subsequent improvement or deterioration becomes difficult to interpret.
Good titration should progressively increase your understanding of the patient's medication response.
Each adjustment should answer a clinical question.
Listen Carefully to Disagreement Between Informants
Parents, teachers, partners and patients may describe medication response differently.
Do not immediately treat this as unreliable information.
Differences can reveal something important.
A teacher reporting excellent improvement while a parent reports little change may indicate that medication is effective during school but has worn off by the evening. Alternatively, the environmental demands may differ considerably.
Ask when and where the reported behaviour occurs.
Disagreement between observers can sometimes provide more useful information than agreement.
Know When to Go More Slowly
Some titrations require greater caution. NICE recommends slower titration and more frequent monitoring in people with relevant coexisting neurodevelopmental, mental health or physical health conditions.
This is particularly important for newly qualified prescribers. There is rarely a prize for completing titration quickly.
If the clinical picture is becoming difficult to interpret, slowing the process can be valuable.
Recognise When the Medication Trial Is Telling You to Change Strategy
Repeated dose escalation should not become an end in itself.
If an adequately conducted trial continues to produce little meaningful benefit, reconsider the treatment strategy.
Similarly, if benefit repeatedly occurs only at doses associated with unacceptable adverse effects, the question may no longer be how to increase the medication. It may be whether this is the appropriate medication or formulation for that patient.
Knowing when not to prescribe more is an important prescribing skill.
Advice for Newly Qualified Prescribers
Early in ADHD prescribing, it is tempting to rely heavily on algorithms. They are useful, but they cannot make the final clinical decision.
At every titration review, try to leave yourself able to summarise the situation in one sentence:
"There has been partial improvement in concentration and task completion, the medication lasts until approximately 3 pm, adverse effects are minimal and physical observations remain satisfactory, so further cautious titration is reasonable."
Or:
"There is good symptom and functional improvement at the current dose, with acceptable tolerability, so there is no clear clinical reason to increase further."
If you can articulate the reasoning clearly, your prescribing decisions and documentation will usually become much more coherent.
When to Seek Senior Advice
Seek senior or specialist advice whenever the clinical picture falls outside your competence or you are uncertain about the safety of further prescribing.
Particular caution is appropriate when there are significant cardiovascular findings or symptoms, substantial weight or growth concerns, significant deterioration in mental state, possible manic or psychotic symptoms, significant substance misuse concerns, complex polypharmacy, diagnostic uncertainty, unusual or severe adverse effects, or uncertainty about prescribing outside standard licensed or guideline-supported practice.
Clinical supervision is not simply for unusual emergencies. Difficult titration decisions are exactly where discussion with an experienced ADHD prescriber can be most valuable.
The Principle to Remember
The central skill in titration is not knowing how to increase a dose. It is knowing why you are increasing it, what outcome you are looking for, and when to stop.
At each review, return to the same clinical balance:
Benefit → Function → Duration → Tolerability → Safety
When that balance is favourable and further adjustment is unlikely to produce worthwhile additional benefit, the patient has reached the point that titration was intended to find: an individually optimised treatment regimen.
5. Summary A concise summary of the key learning points from the lesson.
5. Summary
Medication titration is the process of finding the individual patient's optimal treatment regimen, rather than simply increasing medication through a predetermined sequence of doses. The aim is to achieve meaningful improvement in ADHD symptoms and everyday functioning while maintaining acceptable tolerability and safety.
At every titration review, prescribers should consider five core areas:
Benefit → Function → Duration → Tolerability → Safety
Treatment response should be assessed against the difficulties identified before medication was started. Improvements in education, work, relationships, organisation and everyday functioning are often more clinically meaningful than a simple report that concentration feels "better".
It is important to distinguish insufficient effectiveness from insufficient duration of effect. A medication that works well but wears off too early presents a different clinical problem from one that provides little benefit at any point during the day.
Adverse effects should be actively explored and considered alongside therapeutic benefit. Appetite, weight or growth, sleep, cardiovascular parameters, mood and other relevant physical and mental health changes should be monitored appropriately throughout titration. The optimal dose is not necessarily the dose producing the greatest symptom reduction, but the dose providing the best overall balance of benefit and tolerability.
Titration should be individualised. Some patients respond well to relatively low doses, while others require further cautious adjustment. More complex presentations may require slower titration and more frequent monitoring.
Prescribers should also recognise when not to increase medication. Residual ADHD symptoms do not automatically indicate an inadequate dose, and difficulties caused by medication duration, environmental factors, coexisting conditions or unmet psychological and practical needs may require a different approach.
An unsuccessful medication trial should only be concluded after considering whether the medication has been taken consistently, at an appropriate dose and for an adequate duration. Persistent lack of meaningful benefit or unacceptable adverse effects should prompt reconsideration of the treatment strategy rather than indefinite dose escalation.
Ultimately, good titration depends on repeatedly asking:
Is it working? Is the improvement meaningful? Does it last long enough? Is it well tolerated? Is it safe?
When these questions can be answered satisfactorily and further adjustment is unlikely to provide worthwhile additional benefit, titration is complete and the patient can move into longer-term medication monitoring and maintenance.
6. Further Reading
The following resources are recommended for clinicians who want to consolidate their understanding of ADHD medication titration. UK prescribers should use NICE guidance alongside the current BNF/BNFC and the relevant Summary of Product Characteristics (SmPC) when making individual prescribing decisions.
NICE Guidance
National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management (NG87).
This should be regarded as the principal UK guideline for this lesson. The sections on dose titration, monitoring effectiveness and adverse effects, and medication review are particularly important.
NICE recommends recording ADHD symptoms, impairment and adverse effects at baseline and at each dose change, and titrating medication against symptoms and adverse effects until dose optimisation is achieved. It also recommends slower titration and more frequent monitoring where relevant coexisting neurodevelopmental, mental health or physical health conditions are present.
NICE Guideline NG87 – ADHD: diagnosis and management
British National Formulary
British National Formulary (BNF) and British National Formulary for Children (BNFC).
The BNF and BNFC should be consulted alongside NICE when prescribing. They provide practical information on indications, starting doses, dose escalation, maximum doses, contraindications, cautions, interactions and adverse effects.
This distinction is important for prescribers: NICE provides the overall clinical framework for titration, while the BNF/BNFC and individual SmPC provide medication-specific prescribing information.
Australian Evidence-Based Clinical Practice Guideline for ADHD
Australasian ADHD Professionals Association (AADPA). Australian Evidence-Based Clinical Practice Guideline for Attention Deficit Hyperactivity Disorder. 2022.
This provides an excellent international comparison with NICE and contains dedicated sections on starting and managing pharmacological interventions, medication choice and treatment monitoring. It similarly emphasises individualised dose optimisation, monitoring therapeutic goals and adverse effects, and using information from patients, families and teachers where appropriate.
Australian ADHD Clinical Practice Guideline
Canadian ADHD Practice Guidelines
Canadian ADHD Resource Alliance (CADDRA). Canadian ADHD Practice Guidelines, 4.1 Edition.
The CADDRA guideline provides particularly practical material on medication titration and monitoring across the lifespan. Its titration framework emphasises establishing specific treatment targets, obtaining collateral information where appropriate and maintaining regular contact during titration. It describes the optimal dose as the point beyond which further increases do not produce additional improvement, or where adverse effects prevent further escalation.
CADDRA also provides practical medication resources, including updated information about formulations, duration of action and titration. Some recommendations reflect Canadian licensing and practice and should therefore not replace UK prescribing guidance.
Canadian ADHD Practice Guidelines – CADDRA
European Consensus Guidance
Kooij JJS, Bijlenga D, Salerno L, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European Psychiatry. 2019;56:14–34.
This consensus statement provides a useful European perspective on the assessment and treatment of ADHD in adults. It is particularly helpful for prescribers wishing to place medication management within the broader context of adult ADHD treatment and long-term care.
Landmark Evidence on ADHD Medication
Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738.
This influential network meta-analysis included 133 double-blind randomised controlled trials and compared the efficacy and tolerability of several ADHD medications across children, adolescents and adults. It provides important evidence underlying contemporary decisions about medication selection while also demonstrating that efficacy and tolerability need to be considered together. The authors highlighted the relative scarcity of longer-term randomised evidence.
Read the Cortese et al. systematic review
Recommended Reading for This Lesson
For clinicians completing this lesson, the most useful sequence would be to read NICE NG87 first, particularly the recommendations on dose titration and monitoring, and then review the relevant medication in the current BNF/BNFC and SmPC. The AADPA and CADDRA guidelines can then be used to explore how the same principles of individualised titration are applied in other healthcare systems.
The Cortese et al. network meta-analysis provides useful background evidence for understanding why ADHD medication decisions involve balancing efficacy with tolerability, rather than considering symptom reduction in isolation.
7. Knowledge Check
Question 1
What is the primary aim of ADHD medication titration?
A. To increase the medication until the maximum licensed dose is reached
B. To eliminate all ADHD symptoms
C. To identify a dose that provides meaningful symptom and functional improvement with acceptable adverse effects
D. To ensure that every patient follows the same dose-escalation schedule
Correct answer: C
Explanation: Titration aims to optimise treatment for the individual. This means achieving meaningful improvement in ADHD symptoms and functioning while ensuring that adverse effects remain acceptable and treatment remains safe.
Why the other answers are incorrect:
A is incorrect because the maximum licensed dose is a limit, not a treatment target. Many patients will be optimised at lower doses.
B is incorrect because complete elimination of ADHD symptoms is neither necessary nor always achievable. Functional improvement is particularly important.
D is incorrect because medication response varies considerably between individuals. Titration should be individualised rather than determined solely by a predetermined schedule.
Question 2
An adult taking ADHD medication reports substantially improved concentration and organisation. Occupational functioning has improved, adverse effects are minimal and physical monitoring is satisfactory. They still experience occasional distractibility. What is the most appropriate approach?
A. Automatically increase the dose because ADHD symptoms remain
B. Consider maintaining the current dose if treatment is already optimised
C. Stop medication because it has not eliminated all symptoms
D. Increase immediately to the maximum licensed dose
Correct answer: B
Explanation: Residual ADHD symptoms do not automatically indicate that the dose is inadequate. If there has been meaningful functional and symptomatic improvement with good tolerability, the current dose may already represent an appropriate balance.
Why the other answers are incorrect:
A is incorrect because dose escalation should have a clear clinical rationale rather than being driven by the presence of any residual symptom.
C is incorrect because substantial improvement without complete symptom elimination represents a potentially successful treatment response.
D is incorrect because the maximum licensed dose should never be treated as the routine objective of titration.
Question 3
A 14-year-old reports that their modified-release stimulant works very well during school but appears to wear off before homework. What should the prescriber establish before simply increasing the morning dose?
A. Whether ADHD remains the correct diagnosis
B. Whether the medication is effective while it is active and whether the main problem is duration of coverage
C. Whether the medication can immediately be changed to a non-stimulant
D. Whether all afternoon activities can be stopped
Correct answer: B
Explanation: Effectiveness and duration are separate clinical questions. If the medication provides good symptom control while active but wears off too early, the problem may concern duration or the dosing strategy rather than insufficient therapeutic effect.
Why the other answers are incorrect:
A is incorrect because a medication wearing off does not in itself create diagnostic uncertainty.
C is incorrect because an otherwise effective stimulant does not necessarily need to be abandoned. The formulation, timing and overall treatment strategy should first be considered.
D is incorrect because treatment should be designed around clinically relevant functional needs rather than unnecessarily restricting the patient's activities.
Question 4
A patient's ADHD symptoms improve further following a dose increase, but they develop substantial appetite suppression and worsening insomnia. What principle should guide the next decision?
A. The dose producing the greatest symptom reduction is always optimal
B. Adverse effects are irrelevant if ADHD symptoms have improved
C. Treatment should balance additional benefit against worsening tolerability
D. Continue increasing until the maximum dose is reached and then assess adverse effects
Correct answer: C
Explanation: Optimisation involves balancing therapeutic benefit against adverse effects. A higher dose may improve symptoms slightly more while producing disproportionately greater adverse effects. In such circumstances, a previous dose or alternative strategy may provide a better overall balance.
Why the other answers are incorrect:
A is incorrect because symptom reduction cannot be considered independently of tolerability and safety.
B is incorrect because adverse effects are an integral part of every titration decision.
D is incorrect because adverse effects should be assessed throughout titration, not only after reaching a maximum dose.
Question 5
Which approach provides the most clinically useful assessment of medication response?
A. Asking only, "Do you think the medication is working?"
B. Assessing symptom change without considering functioning
C. Comparing current symptoms and functioning with specific difficulties identified before treatment
D. Using the prescribed dose as the main indicator of effectiveness
Correct answer: C
Explanation: Treatment targets identified before medication provide useful reference points during titration. The prescriber should establish whether changes in symptoms translate into meaningful improvements in everyday life, such as completing schoolwork, managing occupational tasks or reducing impulsive difficulties.
Why the other answers are incorrect:
A is incorrect because a global question may miss important information about the magnitude, timing and functional consequences of treatment response.
B is incorrect because symptom improvement without corresponding functional benefit may require further exploration.
D is incorrect because dose does not determine clinical effectiveness. Response is individual.
Question 6
A parent reports little improvement from medication, while school reports a substantial improvement in concentration and classroom behaviour. What is the most appropriate interpretation?
A. The parent must be mistaken
B. The teacher must be mistaken
C. The reports should be explored in relation to timing, setting and environmental demands
D. The medication should immediately be stopped because the reports conflict
Correct answer: C
Explanation: Different reports may reflect genuine differences across settings. For example, medication may provide good coverage during school hours but wear off before the child returns home. Environmental demands may also differ. Exploring when and where difficulties occur can therefore provide valuable information about treatment response.
Why the other answers are incorrect:
A and B are incorrect because disagreement between observers does not establish that either is unreliable. Both may accurately describe different periods or environments.
D is incorrect because conflicting reports are a reason for further clinical enquiry, not automatically a reason to stop effective treatment.
Question 7
A patient develops irritability during stimulant titration. What is the most useful initial clinical approach?
A. Assume immediately that the stimulant has caused it
B. Ignore it because irritability is unrelated to ADHD medication
C. Establish its timing in relation to baseline symptoms, medication administration, dose changes and medication wearing off
D. Automatically increase the stimulant dose
Correct answer: C
Explanation: Temporal assessment is extremely useful when investigating possible adverse effects. Determine whether irritability existed before treatment, appeared after starting medication, changed following dose escalation, occurs while medication is active or appears as the medication wears off.
Why the other answers are incorrect:
A is incorrect because temporal association needs to be explored rather than causation simply assumed.
B is incorrect because changes in mood or behaviour can be clinically relevant during medication treatment and should be assessed.
D is incorrect because increasing medication without understanding the cause of the irritability could potentially worsen the problem.
Question 8
Which statement about physical monitoring during ADHD medication titration is most accurate?
A. Physical observations are mainly administrative requirements
B. Cardiovascular monitoring is unnecessary when the patient feels well
C. Physical monitoring should be interpreted alongside treatment response and should influence prescribing when clinically significant changes occur
D. Physical monitoring is only required once the final maintenance dose has been established
Correct answer: C
Explanation: Physical monitoring is an integral component of safe ADHD prescribing. Relevant changes in pulse, blood pressure, weight, growth or other physical parameters should be interpreted in the clinical context and acted upon appropriately.
Why the other answers are incorrect:
A is incorrect because observations have a clinical safety purpose and should not become a box-ticking exercise.
B is incorrect because clinically relevant physical changes can occur without the patient necessarily reporting symptoms.
D is incorrect because monitoring is particularly important during titration and following dose changes, as well as during longer-term treatment.
Question 9
A patient has undergone several appropriate dose increases but continues to experience little meaningful improvement despite good adherence and an adequate medication trial. What is the most appropriate next principle?
A. Continue increasing indefinitely until benefit occurs
B. Reconsider whether the medication or treatment strategy is appropriate
C. Continue the ineffective dose permanently because it is well tolerated
D. Conclude that pharmacological treatment can never help the patient
Correct answer: B
Explanation: Lack of response at an initial dose does not establish medication failure, but repeated escalation should not continue indefinitely. Once an adequate therapeutic trial has occurred without meaningful benefit, the prescriber should reconsider the medication, formulation or broader treatment strategy in accordance with relevant guidance.
Why the other answers are incorrect:
A is incorrect because dose escalation must remain within appropriate prescribing limits and have a clinical rationale.
C is incorrect because tolerability alone does not justify continuing medication that provides no worthwhile benefit.
D is incorrect because failure to respond to one medication does not establish that all ADHD medications will be ineffective.
Question 10
Which statement best describes when ADHD medication titration can be considered complete?
A. When the maximum licensed dose has been reached
B. When every ADHD symptom has disappeared
C. When the patient has taken medication for a predetermined number of weeks
D. When meaningful symptom and functional improvement has been achieved with an appropriate duration of effect, acceptable tolerability and satisfactory safety monitoring
Correct answer: D
Explanation: Titration is complete when an individually optimised treatment regimen has been established. The prescriber should understand the degree of benefit, its functional consequences, duration of effect, residual difficulties, adverse effects and relevant safety parameters.
Why the other answers are incorrect:
A is incorrect because many patients are optimised below the maximum licensed dose.
B is incorrect because complete symptom elimination is not required for successful treatment.
C is incorrect because titration is determined by clinical response and tolerability rather than by reaching an arbitrary duration.
Key Message
The central principle running through all ten questions is:
Benefit → Function → Duration → Tolerability → Safety
Good titration is not simply the technical process of increasing medication. It is the clinical process of identifying the lowest appropriate regimen that provides worthwhile, sustained functional benefit while remaining acceptable and safe for the individual patient.
